Loading...
Lantern Pharma Inc.
LTRN•NASDAQ
Healthcare
Biotechnology
$4.24
$-0.02(-0.47%)
Lantern Pharma Inc. (LTRN) Financial Performance & Income Statement Overview
Review Lantern Pharma Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-124169.89%
↓ 124169.89%
Net Income Growth
-130095.59%
↓ 130095.59%
Operating Cash Flow Growth
-24.16%
↓ 24.16%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-83.26%
↓ 83.26%
ROIC
-126.46%
↓ 126.46%
Lantern Pharma Inc. (LTRN) Income Statement & Financial Overview
Review Lantern Pharma Inc.'s (LTRN) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $100654.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $50327.00 | $0.00 | $46266.00 | $4061.00 |
| Gross Profit | $50327.00 | $0.00 | -$46266.00 | -$4061.00 |
| Gross Profit Ratio | $0.50 | $0.00 | ||
| R&D Expenses | $4.27M | $3.72M | $3.89M | $4.25M |
| SG&A Expenses | $1.63M | $1.46M | $1.47M | $1.48M |
| Operating Expenses | $5.85M | $5.18M | $5.36M | $5.73M |
| Total Costs & Expenses | -$5.90M | $5.18M | $5.41M | $5.73M |
| Interest Income | $161393.00 | $191352.00 | $188660.00 | $200950.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $51224.00 | $4389.00 | $46266.00 | $4061.00 |
| EBITDA | -$5.82M | -$5.18M | -$5.41M | -$5.73M |
| EBITDA Ratio | -$57.86 | |||
| Operating Income | -$5.90M | -$5.18M | -$5.41M | -$5.73M |
| Operating Income Ratio | -$58.58 | |||
| Other Income/Expenses (Net) | $21199.00 | $673879.00 | $448955.00 | $291191.00 |
| Income Before Tax | -$5.88M | -$4.51M | -$4.96M | -$5.44M |
| Income Before Tax Ratio | -$58.37 | |||
| Income Tax Expense | $0.00 | $0.00 | $4.00 | $0.00 |
| Net Income | -$5.88M | -$4.51M | -$4.96M | -$5.44M |
| Net Income Ratio | -$58.37 | |||
| EPS | -$0.55 | -$0.42 | -$0.46 | -$0.51 |
| Diluted EPS | -$0.55 | -$0.42 | -$0.46 | -$0.51 |
| Weighted Avg Shares Outstanding | $10.78M | $10.76M | $10.76M | $10.74M |
| Weighted Avg Shares Outstanding (Diluted) | $10.78M | $10.76M | $10.76M | $10.74M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan